1383 related articles for article (PubMed ID: 1826620)
1. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
Watts IS; Wharton KA; White BP; Lumley P
Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
[TBL] [Abstract][Full Text] [Related]
2. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro.
Lumley P; White BP; Humphrey PP
Br J Pharmacol; 1989 Jul; 97(3):783-94. PubMed ID: 2527074
[TBL] [Abstract][Full Text] [Related]
3. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA
Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385
[TBL] [Abstract][Full Text] [Related]
4. ZD9583, an orally effective thromboxane A2 synthase inhibitor and receptor antagonist with a sustained duration of action in rat and dog.
Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
J Pharm Pharmacol; 1997 Feb; 49(2):187-94. PubMed ID: 9055193
[TBL] [Abstract][Full Text] [Related]
5. ZD1542, a potent thromboxane A2 synthase inhibitor and receptor antagonist in vitro.
Brownlie RP; Brownrigg NJ; Butcher HM; Garcia R; Jessup R; Lee VJ; Tunstall S; Wayne MG
Br J Pharmacol; 1993 Dec; 110(4):1600-6. PubMed ID: 8306107
[TBL] [Abstract][Full Text] [Related]
6. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--I. Biochemical profile in vitro.
De Clerck F; Beetens J; de Chaffoy de Courcelles D; Freyne E; Janssen PA
Thromb Haemost; 1989 Feb; 61(1):35-42. PubMed ID: 2546278
[TBL] [Abstract][Full Text] [Related]
7. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
[TBL] [Abstract][Full Text] [Related]
8. Thromboxane A2/prostaglandin endoperoxide (TXA2/PG-END) receptor binding properties in human platelets of ridogrel, a combined TXA2 synthase inhibitor--TXA2/PG-END receptor antagonist.
Heylen L; De Clerck F; Somers Y; Leysen JE
Blood Coagul Fibrinolysis; 1991 Oct; 2(5):617-21. PubMed ID: 1838285
[TBL] [Abstract][Full Text] [Related]
9. The inhibitory effect of GR32191, a thromboxane receptor blocking drug, on human platelet aggregation, adhesion and secretion.
Hornby EJ; Foster MR; McCabe PJ; Stratton LE
Thromb Haemost; 1989 Jun; 61(3):429-36. PubMed ID: 2529661
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
11. The in vivo antiplatelet effects of thromboxane A2 synthase inhibitors are potentiated by simultaneous thromboxane A2/prostaglandin H2 receptor blockade.
Golino P; Ambrosio G; Gresele P; Pascucci I; Ragni M; Russolillo E; Leproux GB; Chiariello M
J Pharmacol Exp Ther; 1993 Aug; 266(2):511-7. PubMed ID: 8355187
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of arachidonic acid induced-aggregation of rabbit platelets with CV-4151 (isbogrel), a selective thromboxane A2 (TXA2) synthase inhibitor: modulation of the antiplatelet action and prostanoid metabolism by rat aortic rings.
Terashita Z; Imura Y; Nishikawa K
J Lipid Mediat Cell Signal; 1996 Jan; 13(1):1-8. PubMed ID: 8821806
[TBL] [Abstract][Full Text] [Related]
14. Comparison of GR32191, R68070 and CV-4151 upon U-46619- and collagen-induced platelet aggregation in vitro and ex vivo.
Watts IS; White BP; Wharton KA; Lumley P
Br J Pharmacol; 1989 Dec; 98 Suppl():842P. PubMed ID: 2611538
[No Abstract] [Full Text] [Related]
15. Preliminary assessment of a novel thromboxane A2 receptor-blocking drug, GR32191, in healthy subjects.
Thomas M; Lumley P
Circulation; 1990 Jan; 81(1 Suppl):I53-8; discussion I59-60. PubMed ID: 2136818
[TBL] [Abstract][Full Text] [Related]
16. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
[TBL] [Abstract][Full Text] [Related]
17. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J
J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694
[TBL] [Abstract][Full Text] [Related]
18. Maximal blockade of TxA2 without compromised PGI2 formation; a superior profile of the TxA2 receptor blocking drug GR32191 over aspirin.
Lumley P; Keery RJ; Wharton KA; White BP; Watts IS
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21B():603-6. PubMed ID: 1825385
[No Abstract] [Full Text] [Related]
19. Agents combining thromboxane receptor antagonism with thromboxane synthase inhibition: [[[2-(1H-imidazol-1-yl)ethylidene]amino]oxy]alkanoic acids.
Cozzi P; Giordani A; Menichincheri M; Pillan A; Pinciroli V; Rossi A; Tonani R; Volpi D; Tamburin M; Ferrario R
J Med Chem; 1994 Oct; 37(21):3588-604. PubMed ID: 7932586
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of the binding of [3H]-GR32191 to the thromboxane (TP-) receptor of human platelets.
Armstrong RA; Humphrey PP; Lumley P
Br J Pharmacol; 1993 Oct; 110(2):539-47. PubMed ID: 8242228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
